Jubilant Pharmova Ltd
JUBLPHARMAJubilant Pharmova Ltd
JUBLPHARMA![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
26.38 | 2.69 | 0.54% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Jubilant Life Sciences Limited is a pharmaceutical and life sciences company.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 5,762.50 | 5,886.29 | 7,557.87 | 9,146.56 | 6,233.67 | 6,389.18 | 6,141.45 | 6,332.30 | 6,795.70 | 7,343.20 | ||||||||||
Raw Materials | 2,157.87 | 2,114.72 | 2,920.96 | 3,523.71 | 1,592.64 | 1,516.38 | 1,550.33 | 1,918.60 | 2,062.50 | 6,033.90 | ||||||||||
Power & Fuel Cost | 366.71 | 333.66 | 424.92 | 466.38 | 112.21 | 105.79 | 134.30 | 166.70 | 148.90 | |||||||||||
Employee Cost | 1,125.09 | 1,230.93 | 1,555.88 | 1,925.96 | 1,843.22 | 1,922.88 | 2,043.39 | 2,166.00 | 2,216.00 | |||||||||||
Selling & Administrative Expenses | 396.06 | 471.69 | 619.21 | 826.54 | 631.50 | 583.30 | 666.14 | 653.90 | 723.20 | |||||||||||
Operating & Other expenses | 456.46 | 365.15 | 478.48 | 909.45 | 281.20 | 594.95 | 589.66 | 657.10 | 820.40 | |||||||||||
EBITDA | 1,260.31 | 1,370.14 | 1,558.42 | 1,494.52 | 1,772.90 | 1,665.88 | 1,157.63 | 770.00 | 824.70 | 1,309.30 | ||||||||||
Depreciation/Amortization | 346.74 | 291.40 | 415.05 | 370.90 | 339.84 | 348.95 | 381.70 | 554.00 | 381.90 | 382.90 | ||||||||||
PBIT | 913.57 | 1,078.74 | 1,143.37 | 1,123.62 | 1,433.06 | 1,316.93 | 775.93 | 216.00 | 442.80 | 926.40 | ||||||||||
Interest & Other Items | 371.35 | 341.11 | 284.28 | 219.81 | 199.71 | 184.10 | 145.49 | 188.20 | 272.30 | 281.40 | ||||||||||
PBT | 542.22 | 737.63 | 859.09 | 903.81 | 1,233.35 | 1,132.83 | 630.44 | 27.80 | 170.50 | 645.00 | ||||||||||
Taxes & Other Items | 150.40 | 161.99 | 216.28 | 329.35 | 335.11 | 296.96 | 216.51 | 88.80 | 93.40 | 92.20 | ||||||||||
Net Income | 391.82 | 575.64 | 642.81 | 574.46 | 898.24 | 835.87 | 413.93 | -61.00 | 77.10 | 552.80 | ||||||||||
EPS | 21.34 | 31.71 | 35.81 | 31.64 | 48.93 | 48.76 | 25.98 | -3.83 | 4.85 | 34.91 | ||||||||||
DPS | 2.60 | 2.60 | 2.60 | 3.91 | 4.34 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | ||||||||||
Payout ratio | 0.12 | 0.08 | 0.07 | 0.12 | 0.09 | 0.10 | 0.19 | — | 1.03 | 0.14 |
Company Updates
Investor Presentation
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Jubilant Pharmova Ltd | 189.15 | 2.69 | 0.54% |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare JUBLPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Jubilant Pharmova Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.6220% | Percentage of the fund’s portfolio invested in the stock 0.96% | Change in the portfolio weight of the stock over the last 3 months 0.56% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/119 (+4) |
HDFC Pharma and Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1053% | Percentage of the fund’s portfolio invested in the stock 1.70% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/39 (-13) |
Kotak Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0451% | Percentage of the fund’s portfolio invested in the stock 1.91% | Change in the portfolio weight of the stock over the last 3 months 1.91% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/35 (0) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
JUBLPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.54%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.43 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 2, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateAug 10, 2023
Dividend/Share
₹5.00
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹5.00
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateMar 9, 2020
Dividend/Share
₹5.00
Ex DateEx Date
Mar 9, 2020
Jubilant Biosys Innovative Research Services,, Singapore (JBIRSPL), subsidiary of Jubilant Biosys (JBL), a wholly owned subsidiary of Jubilant Pharmova, has signed and issued a 'put option offer' to Pierre Fabre Laboratories (PF), which setsforth an offer to acquire 80% equity capital (approx. Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre's R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France. The aforesaid contemplated collaboration is subject to prior consultation of the PF works council and approval of the offer by PF, as well as finalization of definitive agreements and customary closing conditions. Post‐closing of the transaction: - New Company would utilize this R&D Centre with capability to collaborate with Big Pharma & Biotech Customers in Europe & USA. - This contemplated transaction would enable JBL to strengthen its drug discovery capabilities in the fields of biologics and antibody drug conjugates (ADC). - PF may invest 20% equity capital (approx. Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company to transition the R&D Centre into fully independent contract research organization, with PFG having no access to any proprietary information or IP related to the R&D Centre. - PF may also hire services from JBL aggregating to Euro 7 million for first 4 yearsPowered by Capital Market - Live
Firstsource Solutions Ltd, Adani Energy Solutions Ltd, Sapphire Foods India Ltd, Lloyds Metals & Energy Ltd are among the other stocks to see a surge in volumes on NSE today, 01 August 2024.Jubilant Pharmova Ltd recorded volume of 101.02 lakh shares by 14:14 IST on NSE, a 14.89 times surge over two-week average daily volume of 6.78 lakh shares. The stock gained 11.13% to Rs.859.30. Volumes stood at 11.18 lakh shares in the last session.Firstsource Solutions Ltd registered volume of 497.63 lakh shares by 14:14 IST on NSE, a 10.35 fold spurt over two-week average daily volume of 48.08 lakh shares. The stock rose 9.48% to Rs.299.35. Volumes stood at 32.8 lakh shares in the last session.Adani Energy Solutions Ltd witnessed volume of 241.77 lakh shares by 14:14 IST on NSE, a 6.81 times surge over two-week average daily volume of 35.49 lakh shares. The stock increased 11.53% to Rs.1,269.30. Volumes stood at 46.6 lakh shares in the last session.Sapphire Foods India Ltd recorded volume of 9.17 lakh shares by 14:14 IST on NSE, a 6.7 times surge over two-week average daily volume of 1.37 lakh shares. The stock gained 3.13% to Rs.1,703.60. Volumes stood at 1.95 lakh shares in the last session.Lloyds Metals & Energy Ltd saw volume of 34.23 lakh shares by 14:14 IST on NSE, a 6.03 fold spurt over two-week average daily volume of 5.68 lakh shares. The stock increased 7.38% to Rs.785.40. Volumes stood at 4.46 lakh shares in the last session.Powered by Capital Market - Live
Net profit of Jubilant Pharmova rose 7432.81% to Rs 482.10 crore in the quarter ended June 2024 as against Rs 6.40 crore during the previous quarter ended June 2023. Sales rose 9.82% to Rs 1720.40 crore in the quarter ended June 2024 as against Rs 1566.50 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1720.401566.50 10 OPM %14.6210.74 - PBDT194.50114.90 69 PBT103.8025.20 312 NP482.106.40 7433 Powered by Capital Market - Live
Total income increased by 9.41% to Rs 1,745.7 crore in Q1 FY25 as compared with Rs 1,595.5 crore posted in corresponding quarter last year. The growth in total income was led by growth in Ruby-Fill and new product sales in radiopharmaceuticals, volume growth in radiopharmacies, continued growth momentum in Allergy Immunotherapy business and CDMO Sterile Injectables. During the quarter, profit before tax was at Rs 499.70 crore, steeply higher than Rs 25.20 crore posted in the first quarter of FY24. EBITDA jumped 50% to Rs 266 crore as compared to Rs 177 crore during the corresponding period of previous year. EBITDA margin increased to 15.2% in Q1 FY25 as against 11.1% in Q1 FY24. The surge in EBITDA was due to improved performance across all businesses, radiopharma, allergy immunotherapy, CDMO sterile injectables, CRDMO and generics. In Q1 FY25, radiopharmaceuticals revenue grew by 28% YoY to Rs 262 crore. The business continues to maintain leadership in the high margin SPECT imaging product portfolio. Revenue from Allergy Immunotherapy jumped 11% YoY to Rs 168 crore in Q1 FY25. As a sole supplier of Venom in the US, the business is expanding the overall market by increasing customer awareness. In the US Allergenic extracts, the business continues to gain market share. The business is also making inroads in the markets outside of the US. During the quarter, CDMO sterile injectables grew by 27% YoY to Rs 324 crore. The capacity expansion program in Spokane, Washington, USA is on track with respect to time and cost. Line 3 and Line 4 are expected to start commercial production in FY26 and FY28 respectively. Contract research, development and manufacturing organisation (CRDMO) revenue stood at Rs 243 crore in Q1 FY25 as against with Rs 296 crore posted in Q1 FY24. The business is trying to diversify its customer base and in the medium term, it is adding the 'development' capabilitiesin addition to research and manufacturing. Generics business revenue stood at Rs 156 crore in the first quarter of FY25. The business plans to launch 6 to 8 new products per annum in the US and other International markets. The closure of manufacturing operations at the solid dosage formulation facility at Salisbury, Maryland, US has been completed in Q1'FY25. Meanwhile, in June 2024, the consequent to the receipt of stake sale proceeds in Sofie Biosciences, totaling up to $115.9 million, the company made a voluntary debt repayment of $75 million, equivalent to Rs 626 crore. Correspondingly, net debt dropped to Rs 1,869 crore from Rs 2,509 crore as on March'24. Net debt or EBITDA also improved to 1.7x from 2.5x as on March'24. Further, the company said that its wholly owned subsidiary, Jubilant Draximage announced an investment of $ 50 million to expand its PET radiopharmacy network by adding six PET radiopharmacies in strategic locations throughout the United States. The said investment shall position the company in the growing PET Imaging segment and shall also enable it to secure long term contracts with the leading PET radiopharmaceutical manufacturers. The new PET radiopharmacies shall be fully operational in FY28. During the quarter, the company's subsidiary, Jubilant Biosys entered into a power purchase agreement and security subscription and shareholder agreement with Isharays Energy Two, for the purchase of renewable energy generated through captive power arrangement for its facilities located in Noida and Greater Noida. In January this year, the company approved a similar investment to access renewable power through a captive arrangement for its facilities located in Karnataka, India. Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses. The counter hit a 52-week high at Rs 799.95 in intraday today.Powered by Capital Market - Live
Jubilant Life Sciences divests 10% in Safe Foods Corp for Rs 134 cr
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202109/testing-genetic_1200-sixteen_nine.jpg)
Jubilant Ingrevia spurts after its Singaporean arm offloads 10% stake of Safe Foods Corp.
![](https://assets.tickertape.in/images/news-publishers/businessstandard.png)
Jubilant Ingrevia arm divests 10% stake in Safe Foods Corp for $18.2 mn
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2021-09/22/full/1632328838-5818.jpg)
Drug makers Granules India, Jubilant Cadista recall products in US market
![](https://pocket-image-cache.com/direct?url=http://img.etimg.com/thumb/msid-86138521,width-1070,height-580,imgsize-892484,overlay-economictimes/photo.jpg)
Drug firms Granules India, Jubilant Cadista recall products in US market
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2021-02/07/full/1612720523-1442.jpg)
Anurag Roy joins Astec Lifesciences board panel as CEO; Stock dives 4%
![](https://pocket-image-cache.com/direct?url=http://content.indiainfoline.com/_media/iifl/img/article/2014-09/02/full/1409642200-626.jpg)
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -5.77%, vs industry avg of 9.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 4.04% to 1.8%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -33.08%, vs industry avg of 15.17%